Tags

Type your tag names separated by a space and hit enter

A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Contraception. 1992 Jun; 45(6):523-32.C

Abstract

A randomised cross-over trial was performed to compare the pharmacodynamic actions of three low-dose oral contraceptives (OCs): Marvelon (150 micrograms desogestrel (DSG)+ 30 micrograms ethinyloestradiol (EE)), Mercilon (150 micrograms DSG + 20 micrograms EE) and Microgynon (150 micrograms levonorgestrel (LNG) + 30 micrograms EE). None of the OCs produced any significant changes in serum cholesterol, LDL-C and apoprotein B. Triglycerides were increased by the desogestrel OCs but not by Microgynon. The latter however increased the glucose and insulin responses to a glucose tolerance test whereas Marvelon and Mercilon had no effect. HDL-C increased with Marvelon, was unchanged with Mercilon and was decreased with Microgynon. Apoprotein AII was increased by all three OCs but only the DSG OCs increased apoprotein AI. All OCs produced similar increases in caeruloplasmin but the increase in SHBG was much greater with Marvelon and Mercilon than with Microgynon. Testosterone was reduced more with Microgynon than with the DSG OCs. Many of the changes reflect the strong anti-oestrogenic action of LNG on metabolic parameters compared to DSG. Except for the effect on HDL-C, there was little difference between Marvelon and Mercilon on metabolic parameters and this complements the findings from large-scale clinical trials of the two OCs. Mercilon, therefore provides a very satisfactory alternative to Marvelon.

Authors+Show Affiliations

Shanghai Institute of Planned Parenthood Research, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1535580

Citation

Song, S, et al. "A Cross-over Study of Three Oral Contraceptives Containing Ethinyloestradiol and Either Desogestrel or Levonorgestrel." Contraception, vol. 45, no. 6, 1992, pp. 523-32.
Song S, Chen JK, Yang PJ, et al. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception. 1992;45(6):523-32.
Song, S., Chen, J. K., Yang, P. J., He, M. L., Li, L. M., Fan, B. C., Rekers, H., & Fotherby, K. (1992). A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception, 45(6), 523-32.
Song S, et al. A Cross-over Study of Three Oral Contraceptives Containing Ethinyloestradiol and Either Desogestrel or Levonorgestrel. Contraception. 1992;45(6):523-32. PubMed PMID: 1535580.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. AU - Song,S, AU - Chen,J K, AU - Yang,P J, AU - He,M L, AU - Li,L M, AU - Fan,B C, AU - Rekers,H, AU - Fotherby,K, PY - 1992/6/1/pubmed PY - 1992/6/1/medline PY - 1992/6/1/entrez KW - Androgens KW - Asia KW - Biology KW - Carbohydrate Metabolic Effects KW - China KW - Cholesterol KW - Clinical Research KW - Clinical Trials KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Methods--pharmacodynamics KW - Contraceptive Methods--side effects KW - Desogestrel KW - Developing Countries KW - Eastern Asia KW - Endocrine System KW - Ethinyl Estradiol KW - Family Planning KW - Glucose Metabolism Effects KW - Hormones KW - Levonorgestrel KW - Lipid Metabolic Effects KW - Lipids KW - Metabolic Effects KW - Oral Contraceptives, Combined--pharmacodynamics KW - Oral Contraceptives, Low-dose--pharmacodynamics KW - Oral Contraceptives, Low-dose--side effects KW - Oral Contraceptives--pharmacodynamics KW - Oral Contraceptives--side effects KW - Physiology KW - Research Methodology KW - Testosterone SP - 523 EP - 32 JF - Contraception JO - Contraception VL - 45 IS - 6 N2 - A randomised cross-over trial was performed to compare the pharmacodynamic actions of three low-dose oral contraceptives (OCs): Marvelon (150 micrograms desogestrel (DSG)+ 30 micrograms ethinyloestradiol (EE)), Mercilon (150 micrograms DSG + 20 micrograms EE) and Microgynon (150 micrograms levonorgestrel (LNG) + 30 micrograms EE). None of the OCs produced any significant changes in serum cholesterol, LDL-C and apoprotein B. Triglycerides were increased by the desogestrel OCs but not by Microgynon. The latter however increased the glucose and insulin responses to a glucose tolerance test whereas Marvelon and Mercilon had no effect. HDL-C increased with Marvelon, was unchanged with Mercilon and was decreased with Microgynon. Apoprotein AII was increased by all three OCs but only the DSG OCs increased apoprotein AI. All OCs produced similar increases in caeruloplasmin but the increase in SHBG was much greater with Marvelon and Mercilon than with Microgynon. Testosterone was reduced more with Microgynon than with the DSG OCs. Many of the changes reflect the strong anti-oestrogenic action of LNG on metabolic parameters compared to DSG. Except for the effect on HDL-C, there was little difference between Marvelon and Mercilon on metabolic parameters and this complements the findings from large-scale clinical trials of the two OCs. Mercilon, therefore provides a very satisfactory alternative to Marvelon. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/1535580/A_cross_over_study_of_three_oral_contraceptives_containing_ethinyloestradiol_and_either_desogestrel_or_levonorgestrel_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0010-7824(92)90103-Z DB - PRIME DP - Unbound Medicine ER -